Services

BioRunUp


Visit BioRunUp Now!

 In 2010 BioRunUp was created by Mark Messier and Mike Harvilla, two highly successful bio-tech stock traders. The company employs a trading strategy known as the “run-up” method – taking advantage of bullish movements in biotech stocks before key FDA events. This service provides alerts, reports, valuation models, watch lists and members only forum.

Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. These volatile catalysts present an excellent opportunity for traders to profit.

Black Service


Visit the Black Service!

 In 2010 BioRunUp was created by Mark Messier and Mike Harvilla, two highly successful bio-tech stock traders. The company employs a trading strategy known as the “run-up” method – taking advantage of bullish movements in biotech stocks before key FDA events. This service provides alerts, reports, valuation models, watch lists and members only forum.

Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. These volatile catalysts present an excellent opportunity for traders to profit.

Tim Alerts



Visit Timothy Sykes!

 In 2010 BioRunUp was created by Mark Messier and Mike Harvilla, two highly successful bio-tech stock traders. The company employs a trading strategy known as the “run-up” method – taking advantage of bullish movements in biotech stocks before key FDA events. This service provides alerts, reports, valuation models, watch lists and members only forum.

Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. These volatile catalysts present an excellent opportunity for traders to profit.

.

StockGravity Charts



Stock Gravity's Recent Tweets

Gold & Silver Coins